PharmetRx, LLC is a specialty, contract research organization offering a more efficient path to drug discovery, clinical development, and regulatory approval. Our mission is to shorten the timeline and reduce the cost of bringing critical medicines to patients that need them.
Our vision is to continue to accelerate the process of bringing drugs to market by always improving and adding to our proprietary PharmetRx platform. Timelines and cost of bringing drugs to market continue to grow, but PharmetRx’s disruptive technology will reset the bar, helping bring the time to market and total cost down by setting new standards in the drug development process.
In the early days, PharmetRx worked with physician-scientists at the University of Southern California, City of Hope/Beckman Research Institute, University of California Irvine, and the California Institute of Technology, to study the role of genetics and the actions of drugs on human diseases. Initial research efforts focused on correlations between the underlying genetic differences among different patient groups and their differential drug-responses. With the insights that followed, we set to de-convolute the symptoms and uncover the underlying mechanisms of diseases from which these patients suffered. The resulting approach allowed us to then develop novel methods and a comprehensive drug discovery platform, PharmetRx™, to classify diseases, sub-type patient groups, identify key disease pathways, and discover new drugs that were safer and more effective. The first drug developed with PharmetRx™ was licensed to Supernus (NASDAQ: SUPN) and was granted fast-track approval by the FDA and is currently in a final, Phase III clinical trial.